Corina Becker Selected Research

Soluble Guanylyl Cyclase

11/2022	Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
1/2022	Vericiguat in Combination with Short-Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study.
11/2021	Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
1/2021	Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.
11/2020	Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
4/2019	Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
3/2016	Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.
3/2016	Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
3/2016	Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
3/2016	Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Corina Becker Research Topics

Disease

9	Pulmonary Hypertension 01/2018 - 03/2016
7	Heart Failure 11/2022 - 11/2020
5	Pulmonary Arterial Hypertension 04/2019 - 03/2016
2	Hypotension (Low Blood Pressure) 04/2019 - 03/2016
2	Body Weight (Weight, Body) 03/2016 - 01/2014
1	Angina Pectoris 01/2022
1	Headache (Headaches) 04/2021
1	Dizziness (Lightheadedness) 04/2021
1	HIV Infections (HIV Infection) 04/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 03/2016
1	Neoplasms (Cancer) 01/2011

Drug/Important Bio-Agent (IBA)

13	Soluble Guanylyl CyclaseIBA 11/2022 - 03/2016
10	riociguatIBA 04/2019 - 03/2016
7	vericiguatIBA 11/2022 - 11/2020
1	DiureticsIBA 11/2022
1	NitratesIBA 01/2022
1	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2022
1	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2021
1	pro-brain natriuretic peptide (1-76)IBA 11/2021
1	Pharmaceutical PreparationsIBA 04/2021
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 03/2016
1	EnzymesIBA 03/2016
1	Ketoconazole (Nizoral)FDA LinkGeneric 03/2016
1	Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA 03/2016
1	SmokeIBA 03/2016
1	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 03/2016
1	RivaroxabanIBA 01/2014
1	raf KinasesIBA 01/2011
1	ProdrugsIBA 01/2011

Therapy/Procedure

4	Therapeutics 11/2021 - 03/2016
1	Polypharmacy 11/2020
1	Drug Therapy (Chemotherapy) 01/2011